Literature DB >> 10763825

The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.

J Voss1, G Posern, J R Hannemann, L M Wiedemann, A G Turhan, H Poirel, O A Bernard, K Adermann, C Kardinal, S M Feller.   

Abstract

Inappropriate activation of Abl family kinases plays a crucial role in different human leukaemias. In addition to the well known oncoproteins p190Bcr-Abl and p210Bcr-Abl, Tel-Abl, a novel fusion protein resulting from a different chromosomal translocation, has recently been described. In this study, the kinase specificities of the Bcr-Abl and Tel-Abl proteins were compared to the physiological Abl family kinases c-Abl and Arg (abl related gene). Using short peptides which correspond to the target epitopes in known substrate proteins of Abl family kinases, we found a higher catalytic promiscuity of Bcr-Abl and Tel-Abl. Similar to Bcr-Abl, Tel-Abl was found in complexes with the adapter protein CRKL. In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. GTPase analysis with a Ras-GTP-specific precipitation assay showed constitutive elevation of GTP-loaded Ras in cells expressing the leukaemic Abl proteins. The mitogenic MAPK/Erk kinases as well as Akt/PKB, a kinase implicated to negatively regulate apoptosis, were also constitutively activated by both Bcr-Abl and Tel-Abl. The results indicate that the leukaemic Abl-fusion proteins have catalytic specificities different from the normal kinases c-Abl and Arg and that Tel-Abl is capable to activate at least some pathways which are also upregulated by Bcr-Abl.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763825     DOI: 10.1038/sj.onc.1203467

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

3.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

4.  Active site-adjacent phosphorylation at Tyr-397 by c-Abl kinase inactivates caspase-9.

Authors:  Banyuhay P Serrano; Hannah S Szydlo; Dominique Alfandari; Jeanne A Hardy
Journal:  J Biol Chem       Date:  2017-10-24       Impact factor: 5.157

5.  Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.

Authors:  Dan Ma; Qin Fang; Ping Wang; Rui Gao; Weibing Wu; Tangsheng Lu; Lu Cao; Xiuying Hu; Jishi Wang
Journal:  J Biol Chem       Date:  2015-03-23       Impact factor: 5.157

6.  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Authors:  Manabu Kurokawa; Takahiro Ito; Chih-Sheng Yang; Chen Zhao; Andrew N Macintyre; David A Rizzieri; Jeffrey C Rathmell; Michael W Deininger; Tannishtha Reya; Sally Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205

Review 7.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30

Review 8.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

9.  A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature.

Authors:  Carlos A Tirado; Ken Siangchin; David S Shabsovich; Maryam Sharifian; Gary Schiller
Journal:  Biomark Res       Date:  2016-08-25

10.  NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Authors:  Haluk Yuzugullu; Thanh Von; Lauren M Thorpe; Sarah R Walker; Thomas M Roberts; David A Frank; Jean J Zhao
Journal:  Cell Discov       Date:  2016-09-20       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.